SCHEMBL1746839

SCHEMBL1746839

Cc1ccc(Oc2cccc(CO)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.53
LTA4H P09960 1/20 0.53
MMP13 P45452 1/20 0.51
HTT P42858 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC5A2 P31639 1/20 0.48
ALDH1A1 P00352 2/20 0.47
FAAH O00519 1/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
TTR P02766 1/20 0.45
FFAR4 Q5NUL3 1/20 0.45
F10 P00742 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL29196160 0.91 LTA4H (0.56) FFAR1LTA4HHTTTDP1ALDH1A1
SCHEMBL1747441 0.87 ALDH1A1 (0.53) FFAR1LTA4HHTTTDP1L3MBTL1
SCHEMBL30979256 0.87 ALDH1A1 (0.53) FFAR1LTA4HHTTTDP1L3MBTL1
SCHEMBL15474264 0.86 FFAR1 (0.58) FFAR1TSHRSMN1; SMN2FFAR4
SCHEMBL1681007 0.86 SMN1; SMN2 (0.60) LTA4HMMP13HTTALDH1A1FAAH
SCHEMBL29661187 0.85 LTA4H (0.67) FFAR1LTA4HHTTTDP1ALDH1A1
SCHEMBL358425 0.85 LTA4H (0.67) FFAR1LTA4HHTTTDP1ALDH1A1
SCHEMBL8243884 0.84 FFAR1 (0.51) FFAR1MMP13HTTTDP1L3MBTL1
SCHEMBL30979265 0.84 LTA4H (0.55) FFAR1LTA4HTSHRSMN1; SMN2NR1H2
SCHEMBL5112767 0.84 LTA4H (0.55) FFAR1LTA4HTSHRSMN1; SMN2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3383363-B1 TOPICAL PHARMACEUTICAL FORMULATIONS FOR TREATING INFLAMMATORY-RELATED CONDITIONS ANACOR PHARMACEUTICALS INC (US) 2021-01-06 EP disclosed
WO-2017093857-A1 TOPICAL PHARMACEUTICAL FORMULATIONS FOR TREATING INFLAMMATORY-RELATED CONDITIONS ANACOR PHARMACEUTICALS, INC. (US) 2017-06-08 WO disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
US-20140045833-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2014-02-13 US disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7541466-B2 Tetrahydroisoquinoline derivatives for treating protein trafficking diseases GENZYME CORPORATION (US) 2009-06-02 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed
CN-1735408-A Receptor function controlling agent TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-15 CN disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed
US-4411912-A Insecticidal isovaleric acid esters ZOECON CORPORATION (US) 1983-10-25 US disclosed
US-4366325-A Process for the preparation of 3-phenoxy-benzaldehydes BAYER AKTIENGESELLSCHAFT (DE) 1982-12-28 US disclosed
EP-0028714-B1 PROCESS FOR THE PREPARATION OF 3-PHENOXYBENZALDEHYDES BAYER AG (DE) 1982-09-15 EP disclosed
EP-0028714-A1 Process for the preparation of 3-phenoxybenzaldehydes BAYER AG (DE) 1981-05-20 EP disclosed
US-4243819-A Substituted amino acids ZOECON CORPORATION (US) 1981-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 FFAR1 16/4885LTA4H 1418/4885MMP13 3737/4885
US-20140045833-A1 Protein Kinase Inhibitors LCK, BTK, TEC FFAR1 3790/4885LTA4H 4288/4885MMP13 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.